Amneal [AMRX] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

Amneal Pharmaceuticals Inc.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amneal Pharmaceuticals Inc. wins in 6 metrics, Haleon Plc - ADR wins in 14 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amneal Pharmaceuticals Inc. Haleon Plc - ADR Better
P/E Ratio (TTM) 63.23 18.72 Haleon Plc - ADR
Price-to-Book Ratio -57.42 1.88 Haleon Plc - ADR
Debt-to-Equity Ratio 45,095.52 52.37 Haleon Plc - ADR
PEG Ratio -0.30 15.42 Haleon Plc - ADR
EV/EBITDA 10.64 33.08 Amneal Pharmaceuticals Inc.
Profit Margin (TTM) 2.39% 15.11% Haleon Plc - ADR
Operating Margin (TTM) 14.06% 23.17% Haleon Plc - ADR
EBITDA Margin (TTM) 14.06% 23.17% Haleon Plc - ADR
Return on Equity -101.02% 10.27% Haleon Plc - ADR
Return on Assets (TTM) 7.32% 4.67% Amneal Pharmaceuticals Inc.
Free Cash Flow (TTM) $225.64M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return 109.03% -16.01% Amneal Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 1.47 3.78 Amneal Pharmaceuticals Inc.
Enterprise Value $6.86B $122.54B Haleon Plc - ADR
EV/Revenue Ratio 2.27 8.23 Amneal Pharmaceuticals Inc.
Gross Profit Margin (TTM) 36.50% 55.38% Haleon Plc - ADR
Revenue per Share (TTM) $10 $2 Amneal Pharmaceuticals Inc.
Earnings per Share (Diluted) $0.22 $0.50 Haleon Plc - ADR
Beta (Stock Volatility) 1.32 0.33 Haleon Plc - ADR
Short % of Float 3.47% 0.43% Haleon Plc - ADR

Amneal Pharmaceuticals Inc. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

AMRX
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amneal Pharmaceuticals Inc.0.25%18.45%36.13%36.01%30.34%28.28%
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amneal Pharmaceuticals Inc.109.03%497.79%211.54%10.20%10.20%10.20%
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%

Performance & Financial Health Analysis: Amneal Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricAMRXHLN
Market Information
Market Cap i$4.15B$42.40B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,402,9906,594,249
90 Day Avg. Volume i1,913,7237,985,230
Last Close$16.24$9.07
52 Week Range$7.66 - $16.61$8.65 - $11.28
% from 52W High-2.23%-19.59%
All-Time High$24.48 (Aug 20, 2018)$11.42 (Jun 02, 2025)
% from All-Time High-33.66%-20.58%
Growth Metrics
Quarterly Revenue Growth0.12%0.01%
Quarterly Earnings Growth0.11%0.86%
Financial Health
Profit Margin (TTM) i0.02%0.15%
Operating Margin (TTM) i0.14%0.23%
Return on Equity (TTM) i-1.01%0.10%
Debt to Equity (MRQ) i45,095.5252.37
Cash & Liquidity
Book Value per Share (MRQ)$-0.23$4.99
Cash per Share (MRQ)$0.91$0.15
Operating Cash Flow (TTM) i$339.99M$3.56B
Levered Free Cash Flow (TTM) i$197.07M$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: Amneal Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricAMRX (Apr 22, 2026)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i63.2318.72
Forward P/E i11.7815.42
PEG Ratio i-0.3015.42
Price to Sales (TTM) i1.473.78
Price to Book (MRQ) i-57.421.88
Market Capitalization
Market Capitalization i$4.15B$42.40B
Enterprise Value i$6.86B$122.54B
Enterprise Value Metrics
Enterprise to Revenue i2.278.23
Enterprise to EBITDA i10.6433.08
Risk & Other Metrics
Beta i1.320.33
Book Value per Share (MRQ) i$-0.23$4.99

Financial Statements Comparison: Amneal Pharmaceuticals Inc. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMRX (2025)HLN (2025)
Revenue/Sales i3.02B11.03B
Cost of Goods Sold i1.91B3.95B
COGS % of Revenue i63.1%35.8%
Gross Profit i1.11B7.08B
Gross Margin i36.9%64.2%
Research & Development i193.81M316.00M
Operating Income (EBIT) i397.91M2.41B
Operating Margin i13.2%21.9%
EBITDA i606.64M2.81B
EBITDA Margin i20.1%25.5%
Pre-Tax Income i139.21M2.15B
Pre-Tax Income % of Revenue i4.6%19.5%
Income Tax i11.28M472.00M
Income Tax % of Revenue i0.4%4.3%
Net Income (Profit) i127.93M1.68B
Profit Margin i4.2%15.2%

Balance Sheet & Liquidity Metrics

MetricAMRX (2025)HLN (2025)
Cash & Equivalents i282.03M1.26B
Total Current Assets i1.91B4.55B
Total Current Assets % of Revenue i63.3%41.3%
Total Current Liabilities i881.63M4.93B
Total Current Liabilities % of Revenue i29.2%44.7%
Long-Term Debt i2.67B7.75B
Long-Term Debt % of Revenue i88.4%70.2%
Total Shareholders Equity i-71.33M16.48B
Retained Earnings i-535.01M27.85B
Retained Earnings % of Revenue i-17.7%252.5%
Property, Plant & Equipment i107.38M1.00M

Cash Flow Statement Comparison

MetricAMRX (2025)HLN (2025)
Operating Cash Flow i256.93M2.19B
Operating Cash Flow % of Revenue i8.5%19.8%
Capital Expenditures i-96.75M-322.00M
Free Cash Flow i225.64M2.22B
FCF Margin i7.5%20.1%
Debt Repayment i-2.81B-1.35B
Common Stock Repurchase iN/A-654.00M

Short Interest & Institutional Ownership Analysis

MetricAMRXHLN
Shares Short i7.19M19.28M
Short Ratio i3.182.14
Short % of Float i3.47%0.43%
Shares Outstanding i314.57M8.91B
Float Shares i176.28M8.86B
% Held by Insiders i44.04%0.01%
% Held by Institutions i49.74%12.74%
% Held by Public i6.22%87.25%

Dividend Analysis & Yield Comparison: Amneal Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricAMRXHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025